Edge Therapeutics
A biotechnology company, transforms FDA-approved drugs into therapies that address unmet acute neurological conditions.
Launch date
Employees
Market cap
-
Enterprise valuation
€204—305m (Dealroom.co estimates Apr 2015.)
Berkeley Heights New Jersey (HQ)
Financials
Estimates*
EUR | 2017 |
---|---|
R&D budget | 29.0m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | Seed | |
N/A | $630k | Series A | |
N/A | $220k | Seed | |
N/A | $120k | Seed | |
$18.0m | Series C | ||
N/A | $10.0m | Debt | |
$16.5m | Series C | ||
$56.0m | Series C | ||
N/A | N/A | IPO | |
N/A | Merger | ||
Total Funding | €83.2m |
Related Content
Recent News about Edge Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.